Research
Detect disease early
• Lung Cancer Screening
Identify and validate blood borne biomarkers to predict people at high risk of developing lung cancer or patients with undiagnosed disease.
Collaborators: Prof John Field, Dr Michael Davies and Prof Ruwanthi Kolamunnage-Dona
• Cardiovascular Disease Risk Modelling
Improve the accuracy of the CVD risk predictions by developing novel modelling framework that is independent of the COX proportional modelling used to develop QRISK models.
Collaborators: Prof Reecha Sofat and Prof Martin O’Flaherty
Deliver the right drug to the right patients at the right dose
• Pharmacokinetics of vitamin D in healthy adults and children
We developed the world's first accurate PBPK model for mean serum pharmacokinetics profile of vitamin D3 and its active metabolite in healthy adults for an extremely wide range of doses of vitamin D3. Project Details
Model and data on GitHub
We refined this model to predict pharmacokinetics in adults considering body weight. We are further developing a model for children.
Collaborator: Prof Adrian Martineau (QMUL)
• Vitamin D in pancreatic cancer
Modelling the pharmacological effects of vitamin D with a goal of developing an adjuvant therapy to improve patient outcomes.
Collaborators: Prof Bill Greenhalf and Prof Dan Palmer
• Multimorbidity and Polypharmacy
Dose adjustment for polypharmacy treatments with model-based pharmacology analysis
Collaborators: Prof Sir Munir Pirmohamad and Dr Meng Xiaoli
• Nrf2 Modelling
Use of a systems toxicology approach to understand the role of liver metabolism and stress responses in drug toxicity
Collaborators: Prof Ian Copple, Dr Ciarán Fisher (GSK) and Dr Jon Lyon (GSK)
• UNITE4TB
Support the early phase clinical trials of novel anti-tuberculosis drugs for drug-resistant tuberculosis on a worldwide platform
Collaborators: Prof Gerry Davies, Prof Andrea Jorgenson and Dr Dan Carr
• Cancer Patient Stratification
Tumour heterogeneity limits the efficacy of targeted cancer therapies and compromises treatment outcomes. Most patients with advanced cancers treated with appropriately selected targeted therapies ultimately become resistant to the therapy, developing disease progression and succumbing to metastatic disease.
My goal is to develop and validate novel algorithms which combine bioinformatics (genome-scale data characterising the patients, pre-treatments) with PK/PD modelling (tumour size changes in each patient, drug kinetics) to ultimately advise and optimise patient treatment outcomes. I collaborate with Genomics England on this.
PhD opportunity: Personalising cancer treatment with modelling tumour evolution based on genomics biomarkers and PK/PD (Project Description on FindAPhD)
Find new cures to deadly diseases
• Antifungal Drug Discovery
A systems biology analysis of thioredoxin reductase inhibition to support discovery of a novel antifungal treatment
Collaborators: Prof Elaine Bignell (Exeter) and Prof Janet Quinn (Newcastle)
• Long-acting Injectables Development
I am part of the £12M HALo project - the UK National Hub for Advanced Long-acting Therapeutics.
Collaborators: Prof Steve Rannard and Prof Andrew Owen
Research grants
National Hub for Advanced Long-acting Therapeutics (HALo)
ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL
November 2024 - October 2030
Multiomic Lung Cancer Early Detection
CANCER RESEARCH UK (UK)
November 2024 - October 2025